Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Stoke Therapeutics, Inc.

CIK 1623526 STOK·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Revenue recognition change 10-K
  2. Auditor change 8-K +11d
Auditor change SEC item code

Stoke Therapeutics, Inc. dismissed KPMG and engaged EY

The company dismissed the auditor. KPMG → EY No disagreements disclosed.

Evidence
Direction
dismissed
Direction label
The company dismissed the auditor
Disagreements disclosed
No
Item code
4.01
Item title
Changes in Registrant's Certifying Accountant
Predecessor auditor
KPMG
Predecessor tier
big_four
Severity
normal
Source
SEC 8-K item code
Successor auditor
EY
Successor tier
big_four
Why
The company's independent registered accounting firm changed.

Source filing ↗

Revenue recognition change beta Filing comparison

Stoke Therapeutics, Inc. changed its revenue recognition disclosure

Performance obligations are promises to transfer distinct goods or services to the customer.
Evidence
New language
Performance obligations are promises to transfer distinct goods or services to the customer., The consideration may include both fixed consideration and variable consideration.
Prior filed
2025-03-18
Prior form
10-K
Similarity
0.445
Source
revenue recognition note comparison
Threshold
0.6
Why
The revenue recognition policy disclosure changed materially from the previous comparable filing.

Language present now, absent from the prior filing:

  • Performance obligations are promises to transfer distinct goods or services to the customer.
  • The consideration may include both fixed consideration and variable consideration.

Source filing ↗ Prior filing ↗